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Abstract
Most pre-clinical analgesic efficacy assays still involve nociceptive testing in rodents. This is despite concerns as to the
relevance of these tests for evaluating the pain-preventative properties of drugs. More appropriate methods would target
pain rather than nociception, but these are currently not available, so it remains unknown whether animal pain equates to
the negatively affective and subjective/emotional state it causes in humans. Mouse cancer models are common despite the
likelihood of substantial pain. We used Conditioned Place Preference (CPP) testing, assessments of thermal hyperalgesia and
behaviour to determine the likelihood that MBT-2 bladder cancer impacts negatively on mouse welfare, such as by causing
pain. There was no CPP to saline, but morphine preference in tumour bearing mice exceeded that seen in tumour-free
controls. This occurred up to 10 days before the study end-point alongside reduced body weight, development of
hyperalgesia and behaviour changes. These effects indicated mice experienced a negative welfare state caused by malaise
(if not pain) before euthanasia. Due to the complexity of the assessments needed to demonstrate this, it is unlikely that this
approach could be used for routine welfare assessment on a study-by-study basis. However, our results show mice in
sufficiently similar studies are likely to benefit from more intensive severity assessment and re-evaluation of end-points with
a view to implementing appropriate refinements. In this particular case, a refinement would have been to have euthanased
mice at least 7 days earlier or possibly by provision of end-stage pain relief. CPP testing was found to be a helpful method to
investigate the responses of mice to analgesics, possibly on a subjective level. These findings and those of other recent
studies show it could be a valuable method of screening candidate analgesics for efficacy against cancer pain and possibly
other pain or disease models.
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Introduction
An array of nociceptive tests are used to determine the potential
efficacy of new analgesics, and laboratory rats and mice are
overwhelmingly the most widely used test subjects. These tests are
typically classified according to the duration and intensity of the
noxious stimulus and the nature of the response. Acute or phasic
nociceptive assays that apply heat or mechanical stimulation (e.g.
the tail-flick and Hargreaves tests; von Frey, respectively), due to
the largely reflexive nature of the responses obtained, are
considered less appropriate than tonic or sub-chronic tests (e.g.
formalin or carrageenan) that elicit significant and persistent
inflammation [1]. However, the inadequacies of both are well
known [2]. Despite the development of animal simulations of
persistent pain syndromes (e.g. arthritic or neuropathic pain),
concerns prevail as to their clinical relevance. These ultimately
stem from a continuing lack of understanding of how animal pain
equates to the human experience; being a multidimensional
phenomenon including both sensory and affective emotional state
changes (collectively termed ‘life quality’ changes). Theoretically at
least, animal pain and analgesic assays that inform on changes in
these states should afford greater translational validity. This need
has driven recent calls for the development of more clinically
relevant in-vivo models [3,4] providing a more systems-based
approach [5]. This rationale explains why affective (subjective)
state assessment is increasingly being considered as a more
relevant approach to establishing the welfare consequences of
models where animals could be exposed to pain [6–8]. Cancer
models are one research area where considerably more knowledge
on how extensively pain impacts on welfare may be long overdue.
A large and steadily increasing number of animals (mainly mice)
are used in cancer testing (471,000 in the UK in 2012; a 16%
increase on the previous year [9]) with only minimal knowledge
regarding potentially negative impacts on welfare. However, the
guidelines that are meant to minimise suffering in these studies
[10,11] do not incorporate any evaluation of changes in
underlying subjective state, and obtaining evidence of cancer pain
in rodents has relied heavily on assessing underlying nociceptive
changes [12–15], and it seems this is still the case today [16–19].
Our group has extensively assessed changes in naturalistic
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behaviours as a means of assessing post-operative pain in rodents
and other species using both manual [20–26] and automated
methods [27–30], or used a combination of both types of analysis
[31]. However, such behaviour analysis has rarely been used to
assess the effects of cancer, and those few studies that cite ‘pain
behaviour’ actually mean nociceptive or nocifensive behaviours
(i.e. withdrawal or guarding) rather than true spontaneous (e.g.
home-cage) behaviour (see for example [14,32]). Whichever
method of data collection is used, establishing links between
outcome and causation in behavioural studies is difficult because
many factors can contribute to the observed changes. Changes
could occur as an indirect result of procedural influences (e.g.
anaesthesia, hypothermia, dehydration) or factors linked to these
such as fear and associated anxiety. Nevertheless, establishing
whether and when pain arises in cancer studies would have
significant consequences. Firstly it would encourage a more
rigorous approach to ethical decision making by enabling
researchers to apply more effective cost-benefit analyses when
determining if end-points are justified. Improving welfare
standards in this manner would also be beneficial to studies
because unalleviated pain may also jeopardise model validity.
Preventing pain has been shown to be beneficial to validity in at
least one cancer trial [33] and possibly other in-vivo research
applications [34]. Cancer pain is also an area where advances in
human treatments are urgently required. Pain is the most common
and feared consequence of cancer and between 30–60% of
oncology patients continue to report pain prior to, throughout and
following treatment [35]. Indeed, it seems the outlook remains
bleak despite 40 years of attempts to address the problem [36].
Clearly, cancer pain management needs to be refined, and animal
cancer models provide an ideal platform for parallel progress on
welfare advancement and drug discovery. Despite this, cancer
models are not generally used to screen potential analgesics, with
only rare exceptions [13,37]. This may be because most cancer
studies have alternative aims, but could also be due to a lack of
appropriate assessment methods; i.e. those that accommodate
subjective aspects.
Conditioned Place Preference (CPP) testing is widely used to
evaluate the psychoactive (affective) properties of drugs in animals
[38], but usually to identify abuse liability by humans. Animals are
conditioned by being confined in one ‘place’ and pairing that with
drug treatment, whereas in another place they are given only a
placebo. As the ‘places’ have distinctly different cues (usually in
colour or texture) animals progressively associate the drugs’ affect
with the place where they experienced it. If this is a rewarding
experience, either due to the drugs’ positively or negatively
reinforcing (analgesic) effects, animals typically spend longer in, or
visit the drug-paired place more frequently. Provision of analgesia
is a positive experience in painful humans, so if the same applies to
animals then CPP studies have potential for evaluating both the
aversive properties of pain and the analgesic effects of drugs. The
approach has increasingly been applied to research on pain
following the first demonstration that arthritis causes enhanced
CPP to morphine and the N-methyl-D-aspartate antagonist MK-
801 [39]. It was subsequently shown that a bradykinin B1 receptor
antagonist has therapeutic potential against chronic inflammatory
pain [40]. A considerable time later, King et al. showed CPP is
also an effective method for assessing analgesics against neuro-
pathic pain [41]. Qu et al. illustrated the relevance of CPP to
assessing subjective aspects of neuropathic pain in rats by showing
that the rostral anterior cingulate cortex is essential to mediating
pain affect [42]. Rutten et al. were also able to use CPP to
dissociate between the positively and negatively rewarding
consequences of analgesics with opioid-like affects compared to
other mechanisms in a rat inflammatory (carrageenan) model [43].
Davoody et al. then showed increased CPP to clonidine (an a-2
agonist) in rats using spinal cord injury as a centralised pain model
[44]. Okun et al. utilised a similar approach to show CPP to
several different drugs in an osteoarthritic model [45], and most
recently, Park et al. showed absence of positive reinforcement
(reward) to gabapentin in normal mice, but CPP in a polyneuro-
pathic pain model caused by antineoplastic (cisplatin) treatment
[46]. Collectively, these findings clearly demonstrate that the CPP
paradigm is capable of providing animals with a means to report
on their awareness of pain, and so could offer a more appropriate
method of evaluating its centralised (affective/subjective) as
opposed to nociceptive (effective) properties.
The notion that pain could be as complex in animals (at least in
mammals) as it is in humans is underlined by the fact that no single
measurement criterion can (so far) effectively evaluate it. Bateson
et al. originally applied a multiple measures approach to scientific
problem solving (later termed ‘triangulation’) [47], citing that
although ‘‘evidence obtained by different approaches was ambig-
uous’’, ‘‘when the whole body of evidence was considered, much
greater confidence could be placed on a particular meaning’’. In
addressing the problem of animal suffering, and accepting that
‘‘we cannot directly observe an animals’ feelings’’, Bateson
recommended that ‘‘we should use a variety of tasks to gain
confidence in conclusions’’ [48]. Accordingly, studies are now
increasingly applying several different measures in an attempt to
characterise pain more reliably [49,50]. In this study we adopted a
comparable approach by assessing a standard welfare parameter
(body weight) alongside peripheral hypersensitivity testing, mon-
itoring spontaneous exploratory behaviour and conducting CPP
testing. Despite several limitations, hyperalgesia (hypersensitivity)
testing still provides a valuable secondary indicator of pain of
various different modalities including cancer [12,16,19]. Behav-
iour changes are also a common response to pain, but data
collection and analyses are often time consuming, especially if
applied in studies that typically last several weeks; as is usually the
case in cancer studies. Interpretation of these data can also be
problematic because, as has already been described, there are
always alternative explanations for any behavioural changes that
are detected. One often cited possibility is that signs of incapacity
in rodents could be hidden as an adaptive response to reduce the
likelihood of predation; although to our knowledge this has never
been shown unequivocally. To at least partly overcome the time
limitation we used automated behaviour registration software
(HomeCageScan; Clever Systems Inc., VA, USA (HCS)). This
recognises a range (.20) mouse behaviours with comparable
accuracy to manual analysis by a trained observer [27,28]. In this
study we contrasted findings on hyperalgesia and behaviour
changes with the results of CPP testing to assess the consequences
of bladder cancer on the welfare of mice; applying the concept of
triangulation. So far as we are aware, no previous attempt has
been made to evaluate the CPP approach as described here during
tumour development; with consecutive conditioning and testing
cycles. We also sought to gauge (at least hypothetically) whether
this could be a useful approach to screening candidate drugs for
the treatment of cancer pain in humans. We found tumour mice
gained less weight, developed hyperalgesia and showed behaviour
changes that were time-linked to enhanced morphine seeking in
tumour-bearing mice in the 7 days preceding euthanasia. We
concluded that the most likely explanation for these changes was
pain. If not due to pain, at the very least the results indicated
negative impacts on welfare, possibly including malaise. Ordinarily
mice would only be removed from studies after this time,
indicating a likely need for end-point refinement in this mouse
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model of bladder cancer. Our method of applying CPP testing
could also be a potentially useful method of testing the
effectiveness of analgesics intended for cancer and other condi-
tions, especially those where pain can escalate over time.
Methods
Ethics Statement
All work was conducted in accordance with the Animals
(Scientific Procedures) Act 1986 and was subject to local ethical
review. The experiments also adhered to the guidelines of the
Committee for Research and Ethical Issues of the International
Association for the Study of Pain (IASP). All procedures were
approved by the UK Home Office (Project Licence PPL 60/4431).
Subjects and Husbandry
All mice were female C3H/HeN, weighed 25 to 30 g on
delivery (Charles River Laboratories Inc., UK) and had free access
to a commercial pelleted diet (R&M no.3 SDS LTD., Whitham,
UK) and tap water in groups of 10 for one week of acclimation.
They were then housed singly (Macrolon 2 cages; North Kent
Plastics, UK) for another week prior to enrolment. Sawdust and
wood shavings were used as bedding and cages were supplemented
with ‘Sizzle Nest’, an aspen chew-block and a cardboard tube (B &
K Universal). Room temperature was maintained at 2161uC with
15–20 air changes per hour under a 12-hour light cycle (lights off
at 19:00 h). All testing was conducted between 10 am and 3 pm.
Data Collection
The results of 3 studies using separate groups of mice are
described; (1) Hargreaves (nociceptive testing) study, (2) Behaviour
study and (3) Conditioned Place Preference (CPP) testing
consisting of a Pilot dose ranging investigation and then a main
study. The data obtained on studies 1 and 2 were from exploratory
trials undertaken by colleagues of the Northern Institute for
Cancer Research (NICR) using syngeneic MBT-2 (Mouse Bladder
Tumour) cells derived from C3H/HeN/J mice (cells donated by
Prof. Michael O’Donnell (University of Iowa, Iowa City, IA, USA)
and Dr. William A. Larchian (EMH/Cleveland Clinic Prostate
Centre, Cleveland, OH, USA)). The CPP data were obtained from
mice specifically obtained for testing. Our colleague’s objectives
were; initially to characterise the growth profile of orthotopically
implanted bladder tumours (Study 1) and then to refine the
implant methodology (Study 2). However, both studies were an
opportunity to collect supplemental data on pathological effects
(possibly including pain) that would help in the design of the main
(CPP) study; thereby reducing animal use to as low a level as
possible.
Hargreaves Study
This was a pilot study undertaken to establish the growth
characteristics of orthotopically implanted MBT-2 cells that would
inform on the eventual design of the CPP study. Group sizes were
determined by NICR colleagues based on their study require-
ments. Mice were randomly allocated to three groups of 5 that
underwent laparotomy for orthotopic implantation of 100 ml of
Dulbecco’s Phosphate Buffered Saline (DPBS), or the same
volume of DPBS containing 26104 or 26105 MBT-2 cells. A
fourth group of 5 mice were anaesthesia only controls. Eight mice
that underwent surgery were randomly chosen to receive 5 mg/kg
meloxicam (subcutaneously; s/c) to alleviate post-surgical pain
[27], while the remainder received saline (0.3 mls s/c; n = 7).
Anaesthesia was induced with 5% isoflurane in oxygen (5 l/min.)
in a Perspex chamber. Mice then lay in dorsal recumbency on a
heating blanket to maintain body temperatures between 34.5 and
37.5uC and anaesthesia was maintained with 1.5–2% isoflurane in
oxygen (500 ml/min.). Depth was monitored by observing
respiratory rates and regularly assessing toe-pinch reflexes. Simple
eye ointment (Pliva Pharma Ltd., UK) was used to prevent corneal
drying. Surgery was a 0.5 cm midline incision in the skin and
muscles overlying the bladder. Once exposed, 0.1 ml of saline or
the appropriate tumour cell suspension was injected intramuscu-
larly into the bladder wall using an insulin syringe. The abdominal
muscles and skin were closed separately using 5/0 polyglactin 910
(‘Vicryl’, Ethicon Ltd, Edinburgh, UK) and tissue glue (‘Nexa-
band’, Abbott laboratories, Chicago). Anaesthesia lasted approx-
imately 10 minutes.
Thermal withdrawal latencies were obtained at baseline, and at
1 hour and 1 day (24 hours) following surgery, and then on days; 3,
7, 10, 14, 17, 21 and 24 using the Plantar Test (Model 37370; Ugo
Basile, Italy) according to the method of Hargreaves [51]. Animals
were placed in clear acrylic chambers on a glass floor and
habituated for 10 minutes. An infra-red heat source was
alternately applied to the mid-plantar area of each hind paw
(70% of maximum heating capacity; equivalent to 25367 mW/
cm2; 30 second cut-off). This provided a suitable range of response
latencies in normal mice (,between 3 and 8 seconds). Three
responses were obtained from each hind paw with a minimum
interval of 1 minute between ipsilateral recordings. Data were only
obtained from the anaesthesia control mice until day 3 when they
were required elsewhere. Body weights were recorded daily until
day 4, and then on nociceptive test days. As tumours were internal,
growth stage was estimated by daily palpation by an experienced
technician who graded tumours on a 3 point scale; from 1 (barely
present) to 3 (obvious without handling). These inspections also
included a record of activities associated with abdominal pain in
rodents [21,31] and other signs of ill-health such as haematuria,
lethargy, dehydration and poor coat and body condition.
Behaviour Study
The behaviour data were collected as part of a follow-up study
(again without additional animal use) to assess a potentially more
refined (non-surgical) method of cell implantation [52]. Our
colleagues sought to establish if tumour engraftment could be
improved with this method, whereas we wished to evaluate the
longer term effects of cancer growth on behaviour. As before,
group sizes were pre-determined; 20 mice were allocated to the
DPBS group and 20 to the tumour group. Anaesthesia was
induced as previously described but in batches of 5 mice using a
custom-made open-mask gas delivery system. The implant
procedure has already been described, but briefly, the bladder of
each mouse was accessed via a 27 gauge paediatric cannula placed
in the urethra. Urine was voided by gentle supra-pubic pressure
and aspiration, and the bladder mucosa conditioned with a mild
acid rinse (50 ml of 0.1 M HCl) for 20 seconds. This was also
aspirated and then neutralised with 50 ml 0.1 M KOH, and three
DPBS washes. The bladder was emptied before instilling 50 ml of
56106 MBT-2 cells or the same volume of DPBS via a syringe tied
to the tail. The greater cell concentration was in anticipation of an
unknown cell fraction being voided in urine following recovery.
Cells were left in-situ for 30 minutes, following which the mice
were placed in an incubator at 37uC for 20 minutes. Daily tumour
development was monitored as before and body weights were also
recorded daily. Mice were filmed individually for 10 minutes using
a video camera (Sony DCR-HC96, Sony, Japan) positioned on a
tripod 30 cm from the front of clear ‘1284’cages (35620614 cm;
Techniplast, UK Ltd) containing only bedding (Aspen sawdust).
The procedure for behaviour data collection was as previously
CPP Testing for Assessing Pain in a Mouse Bladder Cancer Model
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described [28] except that it was on alternate days before tumour
detection, and then daily. Filming was always during the light
phase but the time of day each mouse was filmed was randomised
within the tumour and control groups.
Conditioned Place Preference Studies
The CPP work was conducted in 2 stages. The first was a pilot
study to explore development of CPP to morphine under repetitive
conditioning and testing cycles, and to identify a morphine dose
for the main CPP study. The chosen dose would be one that
supported only modest place preference but retained sufficient
analgesic properties to elicit negative reinforcement in tumour
bearing mice. Numbers were determined using a retrospective
power analysis on previous morphine CPP results across a range of
dose rates in normal mice (1 and 5 mg/kg s/c) [53] that should
also elicit significant analgesic effects [54,55]. Sample sizes of 8 or
10 were retrospectively found to achieve 79% or 91% power in
detecting significant CPP to a drug (3 or 5 mg/kg morphine)
versus placebo-paired compartment. The CPP apparatus consisted
of black (steel rod floored) and white (steel grid floored)
compartments separated by a grey (solid floored) start chamber.
We used 4 identical testing units (Med Associates, St Albans, VT,
USA; Model CPP-3013AT) equipped with automatically con-
trolled guillotine doors and lights. Compartments housed infra-red
arrays to automatically record compartment residence times and
movements within and between the 3 compartments. An initial
trial was used to determine the baseline compartment preference
of each animal. For this they were placed into the central (grey)
start chamber for 1 minute prior to turning on the lights and
opening the guillotine doors. Preference testing was always
conducted between 10 am and 2 pm. The relative time spent
exploring the black and white compartments over a subsequent
15 minute trial was calculated as a proportion of the total test time
(see CPP data analysis section). The mice were assigned for S+
(saline or morphine) conditioning in the compartment in which
they spent proportionately the least amount of time (i.e. their non-
preferred chamber), but no mice showed proportionate initial
compartment preferences exceeding 0.6 (the CPP analysis section
details the preference calculation method). The design was then
counter-balanced such that the initial relative group preference
approximated as closely as possible to 0.5 (i.e. equal numbers were
assigned per group to the black (B) or white (W) S+ chambers). On
this basis eight mice were allocated to each of 2 morphine groups
spanning the likely range of effective analgesic dose rates (1 or
5 mg/kg s/c) and a representative group of 4 mice were saline
controls. Once we reached the stage of cancer testing we knew the
traditional CPP approach of repetitive conditioning trials followed
by a single preference test would not be appropriate. This was
because if pain occurred; we also wished to capture its onset.
Informed by this, all CPP testing (including in the pilot study)
consisted of repetitive 3 day blocks, with each block comprising 2
days of conditioning before a drug-free preference test each
subsequent day (shown in Figure 1). For the pilot study the 4
controls received only saline (0.03 mls s/c) under both the S2 and
S+ conditions. Because of possible morphine ‘carry-over’ to
afternoon S+ trials it was necessary that vehicle (S2) injections
were always given in the morning and S+ (morphine or saline) in
the afternoon. Morphine was obtained as morphine sulphate
solution (30 mg/ml; NHS Supplies, UK) and was appropriately
diluted with water for injection (wfi) to be administered
subcutaneously in a volume of 0.03 mls. All injections were given
immediately before placement into the allocated B or W
compartment for a 45 minute conditioning period with the
guillotine doors closed. Mice were returned to their home-cages
immediately following each conditioning session. Four consecutive
preference tests were undertaken for the pilot study (4 test blocks;
Figure 1) precisely following the method used to determine the
initial compartment preference.
The main CPP investigation began with a repeat of initial
preference testing. Each mouse was assigned a B or W
compartment for subsequent S2/S+ conditioning in the previ-
ously described manner (balancing numbers initially preferring the
B or W compartment across the control and tumour groups). As
before, mice were assigned to their initially non-preferred
compartment as far as possible. Tumour mice were again
implanted via the urethra with 50 ml DPBS containing
56106 MBT-2 cells. Thirty mice were orthotopically implanted
with tumour cells and ten were saline controls. These numbers
were informed by our previous findings on numbers of graft
failures following urethral implantation. We planned to balance
the design (and further conserve animal usage) by assigning any
such failures to control groups, but only if there were no palpable
or other signs of tumour development after 21 days. Tumour
absence was also confirmed post-mortem. Once the clinical
inspections confirmed tumour growth, each mouse began CPP
conditioning and a treatment matched non-tumour control
entered the study simultaneously. The 3 day series of conditioning
and test sessions then continued until mice were euthanased (see
section on end-point determination). Experimental groups there-
fore formed a 2 (Drug)62 (Treatment) factorial design that
combined conditioning to morphine or 0.9% Saline in tumour or
non-tumour mice. We selected an intermediate dose of morphine
(2 mg/kg s/c) for the main study based on the findings of the pilot
study. In the main CPP study preference tests were also 45 instead
of 15 minutes, but the methodology was otherwise identical to that
used in the pilot study. Due to time constraints and the potential
confound of placement into other unfamiliar environments
(effectively other ‘places’), behaviour and hyperalgesia assessments
were not undertaken as the CPP study progressed. However, the
Figure 1. Timeline of CPP testing. Successive blocks were each of two conditioning days where mice underwent morning S2 (saline) and then
afternoon S+ (morphine or saline) treatments and were confined for 45 minutes in the black or white chamber. The third day of each block was a
drug free preference test, and 3 day cycle was repeated until euthanasia.
doi:10.1371/journal.pone.0103362.g001
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effect of late-stage analgesic treatment on behaviour was assessed
as a potential refinement option. This meant that on euthanasia
days mice were filmed for 20 minutes before and after injection of
the conditioning dose of morphine (2 mg/kg s/c) and identical
recordings were made from an equal number of controls on the
last day of the study.
End-point determination
Clinical inspections were conducted in all studies to determine if
tumour-bearing mice needed to be withdrawn. These were in
accordance with published guidelines [10,11] and with the advice
of highly experienced animal care staff. Euthanasia was unavoid-
able once animals had a large palpable tumour or more than 15%
body weight loss, and if either of these coincided with significant
haematuria (indicated by blood stained fur and/or bedding). All
mice including the controls underwent palpation. They were
restrained in the manner that is usual for an intraperitoneal
injection. The bladder region was then gently palpated between
the thumb and forefinger, but with sufficient pressure to determine
the earliest time of onset of tumour development as reliably as
possible.
Data Analysis
Hargreaves study. As response latencies were initially
similar between the left and right hind-paws, all values were
averaged to calculate the overall mean response latency at each
recording time. The data met the requirements for parametric
analysis so were examined using repeated measures ANOVA with
‘Time’ (10 levels) and ‘Group’ (4 levels; 26tumour; 16placebo and
anaesthesia only) as within and between-subject’s factors respec-
tively. Post-hoc individual time and group comparisons were made
and probability levels adjusted accordingly (Bonferroni). The body
weight changes were also calculated as change from baseline and
the same statistical methods applied. For greater clarity, the weight
changes are depicted as absolute values at each time-point. Due to
absence of nociceptive data in the non-surgery control mice after
day 3 and body weight data after day 4 all analyses following these
times included the surgery groups only. Finally, the effects of pre-
surgery meloxicam were examined by comparing baseline
response latencies to the 1 hour time point in the ANOVA; but
with ‘pre-treatment’ (meloxicam or saline) as a between subject’s
factor (n = 7 (Saline) versus n = 8 (meloxicam)).
Behaviour study. The behaviour data were processed using
HCS automated analysis software. The measures used were total
distance travelled and five behaviour classes comprising different
elements of the 20 individual behaviours the system recognised.
These were: 1) Rearing (comprising ‘Rear Up’ (both partial and
full bipedal extension) & the reciprocal activity ‘Come Down’); 2)
Active behaviour (including walking, running, jumping and
climbing); 3) Abdominal Grooming, and 5) Resting (inactive
periods). We summed the occurrences of behaviours within each
class as the relative magnitude of class elements was sufficiently
uniform. The mean frequency of each class was calculated for each
mouse on each filming day. The relative duration of each class
(duration/frequency) was also calculated to investigate the
possibility that time spent engaging in each type of activity
changed independently of its total occurrence. All behaviour data
were tested and met the assumptions necessary for parametric
analysis. Repeated measures ANOVA was used with ‘Time’ (Days)
and ‘Group’ (Tumour versus Control) as the within and between
subject’s factors for each measurement. Calculations of body
weight change from baseline following non-surgical tumour
implantation were evaluated again with ‘Time’ and ‘Group’
(saline or tumour) as within and between subjects factors, also
using repeated measures ANOVA. Multiple comparisons between
individual times were again probability corrected (Bonferroni).
Conditioned Place Preference Studies. In both the pilot
study and main CPP study the initial black or white compartment
preferences were calculated as the proportionate time spent in
each compartment. Where t = time, the Black (B) compartment
preference (Bpref) was therefore calculated as tB/(tB+tW), and the
White (W) compartment preference (Wpref) as tW/(tW+tB). Thus,
a proportionate score of .0.5 indicated a greater preference for
that chamber and this became the S+ condition. All subsequent
calculations of chamber preference were made in the same way,
and the proportion of time spent exploring the S+ chamber
relative to S2(tS+/((tS+)+(tS2)) was the dependent measure over
successive preference tests. We again used repeated measures
ANOVA to compare S+ preference scores over successive tests in
the pilot and main study with ‘Time’ and ‘Group’ as respective
within and between subject’s factors. The source of any individual
group differences was again determined using post-hoc analyses
and applying Bonferroni correction of probability levels.
Results
All results are expressed as mean61SEM. The electronic files
pertaining to all analyses are publicly available at Dryad (http://
datadryad.org/), or can be accessed by contacting the lead author.
Hargreaves Study
Three mice in the 20 K group had palpable tumours (graded 1–
2) at day 14, and three in the 200 K group reached this stage by
day 10. Thereafter tumour burden gradually increased, and by
day 21 tumours were apparent in all animals such that in several
cases tumours could be identified without need for palpation.
There was no indication of a need to euthanase any mice before
the pre-scheduled study end-point on day 24. As expected, the
anaesthesia controls showed no adverse effects, and aside from the
first day following surgery the saline/surgery controls also
appeared ‘normal’. Figure 2a shows the mean change in
Hargreaves withdrawal latencies (threshold to respond) in the
tumour and control groups over the time course of the study.
Thresholds were initially similar across the 4 groups; between 4.5
and 5.5 seconds; indicating equivalent nociceptive status initially.
Although withdrawal occurred significantly earlier at the 1 hour
time-point in the surgery groups (560.4 vs 360.3 seconds;
(F(1,13) = 16.6, p = 0.001), by 24 hours these showed thresholds
that were no longer significantly different from baseline. This was
also the case in in the anaesthesia controls over their 3 post-
treatment recording days. The surgery controls had also appar-
ently recovered by day 3, and over the time course of the study
their response thresholds remained relatively consistent; from
4.361.4 at baseline compared to 4.361.2 s on day 24. By
contrast, mice implanted with tumours showed an overall increase
in thermal sensitivity (thresholds/latency to respond reduced).
These effects led to a significant overall ‘|Group’ effect (Tumour
vs Control; (F(1,12) = 12.2, p = 0.001) and ‘Group x Time’
interaction (F(18,108) = 2.6, p = 0.001). Post hoc analyses showed
both tumour groups had significantly reduced thresholds com-
pared to DPBS controls arising on day 14 (p = 0.019, 0.001, 20 K
and 200 K vs. DPBS, respectively). This was maintained until day
21 in both groups, but by day 24 only the 200 K group showed
significantly reduced response latencies relative to controls
(p = 0.002). There were no significant effects of meloxicam
(positive or otherwise) on either withdrawal thresholds or body
weight (data therefore not shown).
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As shown in Figure 2b Surgery/Saline mice were somewhat
lighter initially, but not significantly so (,1.5 g). To account for
this ANOVA with individual (post-hoc) comparisons was conduct-
ed on calculations of weight change from baseline over the first 3
days. Post-surgery losses averaged 1.760.3 g overall
(F(1,13) = 32.4, p,0.001). Weights were maintained in the non-
surgery mice. Both tumour (surgery) groups showed this weight
loss from 1 to 3 days, with the greatest mean loss being 2.260.8 g
in the 200 K tumour group on day 1. The 20 K and 200 K
tumour groups both lost significantly more weight than the
anaesthesia controls on post-surgical days 1 and 2 (p = 0.01, 0.003
(day 1); 0.01, 0.04 (day 2), 20, 200 K groups respectively). The
same comparison between the surgery and anaesthesia controls
was not significant, probably because the surgery controls were
initially lighter. The surgery controls therefore lost seemingly less
weight immediately, and had recovered more weight by day 3
than either the 20 K (p = 0.038) or 200 K tumour groups
(p = 0.018). By day 4 there were no significant group differences.
The pattern was then of increased weight until the end of the
study. This resulted in a significant effect of ‘Time’ (F(6,72) = 7.1,
p = 0.002). Groups showed only a modest (,1.5–2 g) increase in
weight, although by the end of the study (days 17 to 24) there was
evidence that weight gain slowed more in the high cell density
group than the other surgery groups. This greater overall
reduction in weight in the last week in the high density (200 K)
tumour group, and over the last 3 days in the 20 K group resulted
in a significant ‘Group6Time’ interaction (F(2,12) = 4, p = 0.045).
Behaviour Study
Of the 20 mice implanted for the behaviour study (non-
surgically) 12 (60%) developed tumours. The implant procedure
caused only marginal weight loss (0.860.1 g), and all mice fully
recovered their starting weights by day 2. The time to detect a
solid tumour mass was relatively uniform (2861.7 days), but
subsequent tumour development was considerably more varied.
The time from tumour detection to reaching end-point criteria
ranged from 10 to 23 days (mean 13.663.5). The first mouse was
euthanased on day 37 following implantation and 2 mice survived
without obvious concerns for 50 days (when the study ended). An
inverse relationship was predicted between ex-vivo tumour wet
weights and survival time (days from detection to euthanasia), but
no such relationship was found; average tumour mass was
1.160.17 g, range 0.4 to 2 g. The net effect of the varied tumour
growth rate was that numbers in the tumour groups were
progressively depleted, so aside from immediately following
implantation, plotting results on a conventional ascending
timescale was not helpful. For both the behaviour and body
weight data we therefore examined the results in reverse of the
time (day) mice were euthanased; predicting this would be the time
when the tumour and control groups would be most distinct. The
data were first standardised by matching those from the tumour
group to equivalent control data (in terms of elapsed study time).
Figure 3 shows the behaviour results from the last 15 days before
each mouse was euthanased, with data from an equivalent elapsed
study time in controls mice. Panels 3a–d respectively show distance
travelled, active, rearing and grooming behaviour frequency. The
ANOVA showed tumour bearing mice travelled significantly less
overall (Figure 3a; F(1,22) = 6.65, p = 0.017), and the group
difference widened as time progressed. This was especially obvious
from 7 days prior to euthanasia when the tumour mice began a
marked decline in activity, whereas the opposite effect was
observed in controls, leading to a significant ‘Group6Time’
interaction (F(14, 308) = 4.1, p = 0.001). There were less obvious
group differences in active behaviour (Figure 3b). The groups were
not significantly different overall, but the pattern of increasing
activity in controls versus a decline in tumour mice was
maintained, but was only marginally significant (‘Group6Time’;
F(14,308) = 2.3, p = 0.04). The last 7 days was again the time when
group differences were most apparent, however, there was a
noticeable spike in active behaviour in tumour mice 3 days prior to
euthanasia that partially impacted on the distance measure.
Rearing behaviour showed the most obvious group separation,
with the tumour mice rearing less during the entire 2 weeks prior
to euthanasia (Figure 3c; F(1,22) = 14.3, p = 0.001). There was no
particularly obvious decline in tumour versus control mice over the
terminal 7 days, but rearing was maintained at a markedly greater
Figure 3. Behaviour study results – Changes preceding
euthanasia. Results of automated behaviour analysis (HCS) during
the period 15 to 1 day prior to euthanasia in the Hargreaves study
(mean6SEM). (A) Tumour mice travelled significantly less distance
overall (‘Group’, p = 0.017) and showed a pronounced decline over the 8
days before euthanasia (‘Group6Time’, p = 0.001). (B) Active behaviour
showed a decline during the days preceding euthanasia (23 to 21). (C)
Tumour mice reared less over the entire 2 weeks prior to euthanasia
than controls (‘Group’, p = 0.001) and (D) groomed more overall
(‘Group’, p = 0.038), but more intensively so over the final 7 study days
(‘Group6Time’, p = 0.048).
doi:10.1371/journal.pone.0103362.g003
Figure 2. Hargreaves study results. The results of nociceptive
testing (A) and recording weight changes (B) (mean6SEM) in mice that
underwent anaesthesia only (Anaes), or anaesthesia followed by
laparotomy for orthotopic implantation of DPBS (100 ml) or MBT-2
bladder tumour cells (26104 or 26105; 20 K or 200 K, respectively)
(n = 5 per group)). (A) Hargreaves recordings were at baseline (Base), 1
hour (1 h), and then on the days indicated by the abscissa. Mice
implanted with the highest cell concentration showed lower Har-
greaves response thresholds (p = 0.02) than the anaesthesia only
controls over the first 3 days (indicating hyperalgesia). Also, beginning
on day 14, mice with tumours developed significant hyperalgesia
compared to surgery/saline controls (p = 0.019, 0.001 (26104 or 26105
groups respectively)). (B) Tumour groups lost significantly more weight
over the first 3 days than either the anaesthesia only or surgery controls
(p#0.04), but mean baseline body weight was recovered in these mice
by post-operative day 4.
doi:10.1371/journal.pone.0103362.g002
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frequency in controls (416690 vs. 2456189). Grooming showed a
slight overall increase in both groups over time (‘Time’ factor
significant; F(14,308) = 2.1, p = 0.05; Figure 3d). The tumour mice
also groomed more frequently overall (F1,22) = 4.9, p = 0.038), but
again, the major effect in tumour mice was an increase in
grooming frequency over the final 7 days (significant ‘Group x
Time’ interaction; F(14,308) = 2.1, p = 0.048). This result was
rendered only modestly significant due to another incongruous
effect 3 days prior to euthanasia when grooming frequency fell in
tumour mice. Rest periods (inactive behaviour) were no more
frequent in control or tumour mice until the final 3 days when
tumour mice tended to show a reduction compared to only a very
slight increase in controls (not shown).
The body weight data on the day each mouse was euthanased
were matched as previously described: with results in tumour mice
matched to data from an equivalent elapsed study time in a
randomly chosen non-tumour control. This was repeated for each
day prior to euthanasia. Figure 4 shows the mean body weights of
the control and tumour groups from 37 days prior to euthanasia.
The pre-study weights of the 2 groups were not significantly
different. Both groups were gaining weight 37 days prior to the
eventual study end, however, the tumour group stopped gaining
weight 2 weeks later (22 days before euthanasia). ANOVA showed
a significant ‘Group6Time’ interaction 12 days prior to euthana-
sia (F(1,23) = 8.55, p = 0.008). Post-hoc analyses (independent
samples t-tests) showed that by this time the mean weight of
tumour bearing mice was 2561.1 g, compared to 2661.3 g in
controls (p = 0.015). The control mice then steadily increased in
weight whereas the reverse occurred in the tumour group (or at
least they continued to fail to gain weight). By the end of the study
(on day 21) the mean weight of control mice was 2761.8 g
compared to 24.562.5 g in the tumour group (p = 0.009). In the
tumour mice this amounted to a proportional weight loss of 4.6%
compared to the time when they were heaviest (Day 24 prior to
euthanasia). We tried to minimise any masking effect of underlying
tumour burden on this weight estimate by subtracting ex-vivo
tumour wet weights, but did not find mice with larger tumours lost
significantly more weight.
Conditioned Place Preference Studies
The results of the CPP pilot study are shown in Figure 5
according to mean S+ preference scores of the groups given saline
and each morphine dose. ANOVA indicated a significant overall
‘Group’ difference (F(1,2) = 5.6, p = 0.013). The post-hoc analysis
showed mice given 5 mg/kg morphine had significantly elevated
S+ scores over tests 2 to 4 compared to the saline controls
(p = 0.005) or the mice given the lower morphine dose (p = 0.041).
Saline was predictably ineffective, but as 1 mg/kg morphine was
also not different from saline an intermediate morphine dose of
2 mg/kg was chosen for the main CPP study.
Figure 4. Body weight in catheterised mice (implanted non-surgically). The mean (6SEM) body weight of groups of mice implanted
orthotopically with either MBT-2 tumours (56106 cells/mouse; 50 ml) or an equal volume of saline, and used to collect behaviour data (n = 12 per
group; graft successes only). As in Figure 3, data on days prior to euthanasia are shown following time matching (equivalent elapsed study time).
Tumour-bearing mice were significantly lighter than controls from day 12 (‘Group’; p = 0.008) and progressively lost more weight until the study end.
doi:10.1371/journal.pone.0103362.g004
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Implant success in the main CPP study was 70% with 21 of the
30 implanted mice developing tumours. As planned, four non-
growth mice were randomly assigned to control groups, one of
which subsequently developed a tumour (so data were rejected).
Although overall engraftment was improved from that seen in the
behaviour study, the time from implantation to detection of a solid
tumour mass over the bladder was more varied. Of the mice where
grafts were successful, 75% presented tumours within 14–21 days.
Subsequent rates of tumour development were also varied, leading
to a broad range of times from tumour detection to the time that
mice were euthanased (13–46 days). This meant the number of
tests conducted in tumour mice before they reached the endpoint
criteria ranged from only 4 to 15 CPP trials (mean 6 SD;
8.462.73). To minimise the impact of this variation we re-applied
the selection procedure to focus on the times likely to reveal group
differences; where tumour-bearing mice should show an enhanced
morphine preference if they were experiencing pain. As the
minimum number of tests was four, the results of the last 4 tests
prior to euthanasia were examined (i.e. CPP tests 24, 23, 22 &
21); equivalent to days 10, 7, 4 and 1 day before the study ended.
As in the behaviour analysis, data from the non-tumour control
(saline or morphine) groups were time-matched as far as was
possible to the total number of cycles of conditioning/preference
testing undergone by individuals in the equivalent tumour groups.
There were no significant differences in S+ scores between the
morphine and saline treated mice on the 3 test days after tumour
detection, and both the normal and tumour bearing mice trained
only to saline displayed essentially equal preference to the S+ and
S2 chambers over these trials (i.e. preference scores close to 0.5;
data not shown). This illustrated that the apparatus and study
design were unbiased. As predicted, the responses to morphine
were clearer over the last 4 preference trials (Figure 6). From 10 to
4 days before euthanasia (preference tests 24 to 21) there was
little change in morphine preference in controls, but the
morphine-treated tumour mice displayed the highest S+ place
preference scores of all four groups; the combined effect being an
overall significant effect of drug treatment (F(1,29) = 4.9,
p = 0.035). The morphine preference in the tumour group
increased over the final 3 preference tests (7 days). Mean S+
preference over this time was calculated and results compared
between groups using ANOVA. This also showed a significant
overall treatment effect (F(3,29) = 6.74, p = 0.001). Post-hoc tests
showed tumour mice conditioned to morphine had significantly
elevated S+ scores in comparison to both the saline controls
Figure 5. CPP pilot study results. Mean S+ chamber preference scores (6SEM) across 4 successive tests in mice conditioned to saline (0.03 mls;
n = 4) or morphine (Mor) at 1 or 5 mg/kg (n = 8/group). Mice were conditioned in their initially non-preferred chamber (Pre). Scores above 0.5 (dotted
line) indicate enhanced S+ (morphine or saline) chamber preference. Arrowed lines at the top of the chart denote the time period over which the
preference for 5 mg/kg morphine exceeded 1 mg/kg (p,0.05; dashed arrowed line) or saline (p,0.01; solid arrowed line).
doi:10.1371/journal.pone.0103362.g005
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(p = 0.005) and the saline tumour mice (p,0.001). The key
comparison, however, was between the morphine preference
scores of the tumour and control mice. Mice with tumours had a
significantly greater preference for the morphine paired chamber
than the morphine controls (p = 0.02). These findings were
consistent with the notion that mice in pain will show a place
preference to a compartment paired with an analgesic drug over
one paired with only saline, but crucially, more so than the drug
preference shown by normal mice.
Analysis of the body weight data indicated there were no
significant group differences at baseline (before cell implantation).
Body weights from the time period over which the CPP results
indicated was the most important phase of the study were then
assessed; the final 4 preferences tests (Figure 7). We used
calculations of change in weight from before the previous test
day (14 days prior to euthanasia). Repeated measures ANOVA
was used with ‘Time’ (4 levels) as a within-subjects factor, and both
‘Drug’ (morphine or saline) and ‘Treatment’ (cancer or control) as
between subject’s factors. Over the final 10 days of the study the
tumour bearing mice showed a small but nevertheless significant
reduction in weight (1.660.8) compared to non-cancer mice. The
non-cancer groups either maintained body weight or showed a
marginal weight increase during this period (0.661 g) (significant
‘Time6Treatment’ interaction; F(2,50) = 11, p,0.001). Morphine
had no significant effects on body weight.
There was only a marginal difference in mean tumour burden
between the saline and morphine groups; tumour wet-weight at
post-mortem was 1.0460.75 in the saline group versus
0.8360.45 g in mice conditioned to morphine. An independent
samples t-test showed morphine was unlikely to be responsible for
this very slight difference (t(16) = 0.91, p = 0.4). We initially
explored whether tumour burden was a significant contributor
to morphine chamber preference on the last CPP test (Preference
test P-1). Pearson’s correlation showed no significant relationship
between S+ preference scores and tumour burden in the saline
group (r =20.19; p = 0.64; Figure 8a), however, tumour burden
was significantly positively correlated with preference for the
morphine paired chamber (r = 0.70; p = 0.034; Figure 8b). The
same relationship between tumour burden and morphine seeking
was also apparent at 4 days (Preference test P-2) before euthanasia
(r = 0.72; p = 0.029 (not shown)). However, the same comparison
at the P-2 time point in mice conditioned to saline was not
significant (r = 0.22; p = 0.59) (P-2 data not drawn)). These results
therefore showed that increasing tumour burden made a positive
contribution to morphine chamber preference.
The final phase of data collection in the CPP study was to
determine whether we could recognise any behaviour-based
evidence of reduced pain following terminal morphine treatment.
We assessed the effect of the training dose of morphine given on
the last study day on grooming, rearing and inactive behaviour
Figure 6. CPP morphine preference scores preceding euthanasia. Mean S+ chamber preference scores (6SEM) during the last 4 preference
tests (actual days in brackets) prior to euthanasia (Day 21(1)) in normal (Control) and tumour bearing (Cancer) groups conditioned to Saline or
Morphine (2 mg/kg; s/c). Scores above 0.5 indicate an enhanced S+ chamber preference. Note especially the cancer mice conditioned to morphine
show enhanced morphine seeking (higher CPP S+ score) than either the saline or tumour control groups (p = 0.005; p,0.001, respectively), but from
days 27 to 21 prior to euthanasia their morphine chamber preference also significantly exceeded the morphine preference of controls conditioned
to morphine (p = 0.02).
doi:10.1371/journal.pone.0103362.g006
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frequency (Figure 9). For reasons previously given, total distance
travelled was the only measure needed to evaluate changes in
active behaviour. The analysis used ‘Time’ (pre and post-
morphine) and ‘Group’ (tumour vs. non-tumour) as within and
between subject’s factors, and post-hoc analyses (Bonferroni)
identified individual group differences. Prior to morphine the
tumour-bearing mice travelled significantly less distance than
controls (F(1.28) = 6.4, p = 0.017; Figure 9a). This increased in all
mice following morphine (‘Time’ factor significant; F(1, 28) = 9.2,
p = 0.005). Rearing frequency was similar across all groups
initially, and all groups showed significantly reduced rearing
behaviour following morphine (‘Time’ factor significant;
F(1,27) = 83, p,0.001; Figure 9b). The mice with tumours initially
groomed more than controls (F(1,28) = 104, p = 0.001), and
morphine had no significant effect on this in either control group,
and no significantly greater effect in tumour mice irrespective of
whether they had previously been exposed to morphine (Fig-
ure 9c). Inactive behaviour was significantly more frequent in the
controls versus the tumour groups prior to morphine
(F(1,28) = 11.2, p = 0.002; Figure 9d), but all mice rested more
frequently following drug treatment (F(1,28) = 36.7, p,0.001).
Discussion
The work had two main aims. The first was to determine
whether a relatively common mouse bladder cancer model had
negative impacts on welfare, including effects caused by malaise,
anxiety and ultimately pain. If there were any such effects we
hoped to highlight these and provide information on potential
refinements to prevent possible suffering in similar studies in the
future. A second aim was to determine whether the Conditioned
Place Preference (CPP) test provides a potentially more relevant
alternative to testing analgesics against cancer pain than other
presently available methods. The work consisted of a series of
studies where in addition to CPP testing, we investigated the
development of hyperalgesia, behaviour changes and potential
prophylactic effects of morphine in terminal-stage cancer-bearing
mice.
In the first study the Hargreaves method was used to evaluate
any development of thermal hyperalgesia over a 24 day period
following surgical implantation of bladder tumour cells. We found
withdrawal thresholds reduced between 10 to 14 days prior to
euthanasia, and this hyperalgesic effect was maintained until the
end of the study. This increase in peripheral sensitisation provided
our first evidence that this type of cancer might progressively
impact negatively on welfare. A subsequent investigation exam-
Figure 7. Body weight change in mice used in CPP testing. Mean weight (6SEM) on days 210 to 21 prior to euthanasia relative to weight
observed on day 214 in mice in the main CPP study. Weights in tumour-bearing mice significantly declined over the final 7 study days compared to
control groups (‘Group (Cancer vs Control)6Time’, p = 0.001), with no apparent effect of morphine.
doi:10.1371/journal.pone.0103362.g007
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ined changes in the behaviour of mice implanted with tumours via
a potentially more refined non-surgical approach. Recordings of
behaviour were processed using an automated system. This
showed abnormal behaviour changes began between 7 and 10
days before the study ended, with the most notable effects being
reduced distance travelled, reduced active and rearing behaviour
and increased abdominal grooming. Changes to behaviours such
as these have previously been attributed to abdominal pain in mice
[30,31,56] and are similar to those that occur post-operatively in
rats [21]. However, the most conclusive evidence that the mice
actually experienced pain came from the CPP study. Morphine
seeking was found to be significantly positively linked to tumour
burden, but most importantly, tumour bearing mice developed a
greater preference for the morphine-paired chamber than any
other group. They may also have found the placebo-paired
chamber aversive, but the pattern of drug seeking strongly
indicated the change in compartment preference was due to the
negatively reinforcing (pain relieving) properties of morphine. As
with the nociceptive and behaviour changes, the changes in
morphine-seeking primarily emerged during the last 10 days of the
study (4 preference tests). This not only indicated the presence of
pain, but showed CPP testing could be a potentially effective and
relevant means of evaluating analgesics against cancer and other
types of pain.
Our findings were obtained despite a number of challenges,
mainly the variable success of implanting tumours and the
subsequent rates of cancer growth. Although engraftment was
100% using the surgical approach, it dropped to only 60% on our
first attempt to implant via the urethra, then improved to 70% in
the CPP study. There were several reasons why we persisted with
non-surgical implantation of tumours despite the lower graft
success. This method initially offered the possibility of being less
costly, both financially and in terms of welfare. Conditioning of the
bladder epithelium using a mild acid rinse and subsequent
buffering was meant to maintain graft success but be less invasive.
Non-surgical implantation also meant there was a reduced
likelihood of needing to provide peri-operative analgesics; an issue
that often concerns researchers who wish to rule out non-specific
influences on tumour development. Potential welfare benefits were
indicated by an absence of post-procedural weight loss compared
to the effects of surgery. Mice that underwent surgical implanta-
tion also showed reduced thermal response thresholds, both
immediately following surgery and during the latter stage of cancer
Figure 8. Relationship between morphine seeking (CPP score) and tumour burden. Scatterplots showing: (A) the relationship between
relative S+ preference scores for saline on the day immediately prior to euthanasia versus post-mortem (wet) tumour weights (day P-1; Pearson’s
Correlation); and (B) the same relationship between tumour weight and S+ chamber preference on day P-1 for mice exposed to morphine. Tumour
mass bore no significant relationship with saline chamber preference, but as panel B shows, morphine seeking significantly increased with increasing
tumour burden.
doi:10.1371/journal.pone.0103362.g008
Figure 9. Behaviour changes following terminal morphine.
Behaviour results showing the mean (6SEM) frequency before and
30 minutes after terminal-stage treatment with morphine (2 mg/kg s/c)
in tumour (Tum) or control (Ctrl) mice that underwent CPP testing and
were conditioned to morphine (Mor2) or saline (Sal). (A) Distance
travelled; (B) Rearing; (C) Grooming; (D) Inactive periods (Pre) and
following (Post) morphine treatment (2 mg/kg s/c). Morphine signifi-
cantly increased overall activity, indicated by increased distance
travelled and reduced rearing (‘Time’; p = 0.005; p = 0.001, Distance
and Rearing respectively). Grooming was reduced by morphine but not
significantly, and inactive frequency increased (‘Time’, p,0.001,
respectively).
doi:10.1371/journal.pone.0103362.g009
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growth; albeit unfortunate that we had no comparable nociceptive
data from the catheterised mice. Finally, stress such as caused by
surgery is a known tumour growth promoter [33,57], and any
more rapid development could have been detrimental to the
eventual timescale for CPP testing. Although tumour seeding was
lower and subsequent growth slower via the urethral route, a
positive aspect was that this allowed more time for CPP
conditioning and also accommodated our preferred approach of
only recruiting mice once tumours were detected. Establishing the
most appropriate time to begin CPP testing was important since
conditioning disease/pain-free mice to morphine could have had
other unwanted consequences; e.g. tolerance issues or opioid-
induced hyperalgesia. Avoiding these may have been important in
our eventual ability to illustrate greater morphine seeking in
tumour mice. Directly incorporating nociceptive testing was
initially considered in determining when to begin conditioning
(i.e. when thresholds reduced), but would have added a further
unknown and potentially confounding variable; effectively a third
compartment/place to which mice would have been exposed for
relatively long periods. From an oncology perspective, however,
implanting mice via the urethra may not have been the best
option. This is because there are also valid welfare arguments in
favour of surgical implantation, especially when tumour growth is
more varied. Such variation could increase the number of animals
needed to achieve adequate statistical power; making it even more
challenging to determine an appropriate study end-point. The
longer study duration would also increase facility (housing/
husbandry) costs; an obviously important factor in overall cost-
benefit analyses.
The behaviour study was meant to establish if bladder cancer
impacted on aspects of behaviour in a similar way to other sources
of abdominal pain in mice (e.g. vasectomy [31]), and thus required
extensive collection of video footage for automated analysis using
HCS software. We have previously used this system to assess the
behaviour of mice, and shown it can provide precision equivalent
to manual scoring [27,28]. However, this was where the varied
tumour growth had its first major impact; forcing us to apply the
data matching procedure to meaningfully analyse the results. We
evaluated responses across 5 behaviour categories during the 2
weeks before euthanasia. This was the period of tumour growth
considered most likely to encompass the time of development of
any tumour-related pain. Abdominal grooming was more frequent
in tumour-bearing mice, whereas distance travelled was reduced,
and active behaviour and rearing all occurred substantially less
frequently than in controls, especially over the final 7 days prior to
euthanasia (Figure 3). There were, however, some unexpected
findings. There was an increase in active behaviour and reduced
grooming in tumour mice 3 days before euthanasia (Figures 3b
and d), and another decline in active behaviour in controls on day
28. We looked for some unplanned event as a possible
explanation (e.g. unscheduled husbandry), but the laboratory
records held no clues. An adverse reaction to palpation was also
unlikely as this was repeated on each of the 2 days that followed
without any apparent impact. The effects were also unlikely to
have been due to the data manipulation procedure as the period
over which matching was conducted spanned 2 weeks and 7
separate dates. Indeed, we cannot offer a more rational
explanation, and can only state that some mice were prone to
some unusual activity patterns. Nevertheless, the clear disparity
between the control and tumour mice over the period preceding
euthanasia highlighted this as a key period for later evaluation in
the CPP study.
The morphine doses chosen for the CPP pilot study (1 and
5 mg/kg) was another key decision. This was based on evidence of
significant anti-nociceptive effects in both phasic (thermal) and
tonic (abdominal writhing) tests in mice [54,55]. The larger dose
had also previously been shown to elicit relatively robust CPP in
rats, whereas 1 mg/kg was only marginally effective [39]. As non-
tumour mice in the pilot study developed CPP to 5.0 or 1.0 mg/kg
morphine in as a few as two to four conditioning trials (Figure 5)
an intermediate dose of 2 mg/kg was chosen for the main study.
However, the apparent speed of development of CPP, even in
mice given 1 mg/kg, necessitated extending the amount of time
used for later preference trials. Exploration time was increased to
45 minutes in the main study, however, only the first 15 minutes
served as the dependent measure of preference. This was done in
an attempt to minimise CPP development in non-tumour control
mice as drug-free tests of this length can serve to facilitate
extinction. The design of the main CPP experiment was informed
by the original studies where the potential of CPP for evaluating
the negatively reinforcing (i.e. analgesic) properties of drugs.
Initially, arthritic rats showed an enhanced choice preference to a
morphine paired chamber relative to drug treated controls [39]
and it was concluded that this was because morphine was more
rewarding in the context of pain. However, this interpretation was
somewhat obscured in that non-inflamed rats showed an
equivalent chamber time preference, and only the choice measure
was significant. Sufka [39] describes some possible reasons; one
being that choice testing could be a more relevant measure of
response strength, whereas time could be influenced by factors
unrelated to reinforcement. The intrinsically rewarding properties
of morphine also presented challenges of interpreting uncondi-
tioned responding (the animals’ subjective state), and why choice
was superior to time. Then, however, a series of 6 discrete trials
was used over 3 days of testing. Although we could not conduct
similar choice trials due to a greater burden of conditioning and
testing, we investigated the surrogate measure of entrances to each
compartment over the first 60 s of each preference test. This,
however, did not prove more informative than time preference so
the results were not presented. Sufka’s original conclusion
regarding the value of the CPP methodology in the context of
negative reinforcement was ultimately strengthened when a
Bradykinin B1 antagonist was used, which unlike morphine, had
no intrinsically rewarding effects but was also preferred by
formalin treated versus control rats [40]. This highlighted CPP
as a method that could be applied outside of its usual domain for
testing the abuse liability of drugs, and it has since been applied in
several neuropathic and inflammatory pain models, all of which
have successfully used ‘time’ as the dependent measure of
unconditioned responding [41–43,45,46]. These studies, and the
results presented here show CPP testing is one of the very few
methods with potential for effectively differentiating between the
sensory (nociceptive) and affective dimensions of pain. We know of
only one previous study where the CPP methodology has been
used to assess cancer pain [58], and this failed to show CPP to
morphine 24 days after development intra-plantar melanoma.
Notably, they used a much higher morphine dose than in our
study (10 mg/kg), so the lack of effects may have been due to
tolerance issues or drug-induced hyperalgesia; both very common
effects of repetitive opioid treatment. There was little evidence for
either in our study since there were no differential behavioural
responses to terminal morphine treatment in pre-exposed or drug
naı¨ve mice. Additionally, the morphine preference of controls
changed relatively little from 10 to 4 days before euthanasia,
whereas drug-seeking significantly increased over the same time
period in the tumour mice. Tolerance would presumably have
increased drug seeking in controls, and conversely, hyperalgesia
should have prevented this in cancer mice. In reality, however, we
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may actually have underestimated when pain began because the
first time that the cancer-bearing morphine group showed
significantly elevated morphine seeking was 7 days (3 preference
tests) before euthanasia. As learning this association could
conceivably have required several conditioning cycles, the actual
time when pain (and its relief) became salient cues may have been
at some earlier time point.
Since the tumour model described by Betourne et al. [58]
should still have caused localised pain, another possible explana-
tion of their negative findings could be that the mice were so
incapacitated that they were insufficiently motivated make a
chamber choice. However, other design differences could also
offer an explanation. As in Sufka’s original study [39], all other
studies where the CPP paradigm has been applied to pain have
used the traditional approach of conditioning (using one or several
drug exposures) followed by preference testing. We applied CPP
testing where there could be severe, but slowly developing pain,
but additionally, we wished not only to assess its presence but
capture its onset. This meant applying a radical design change,
incorporating repeated sets of conditioning trials interspersed with
multiple preference tests (see Figure 1). So far as we are aware this
approach has not been used previously and our positive result
may, at least in part, have been due to the more frequent
conditioning trials consolidating the association between pain and
drug treatment. Our method of processing results by matching
mice according to the total number of conditioning and test cycles
undertaken, though again unconventional, may also have helped
clarify the main effects. As in the behaviour study, this was needed
to minimise the impact of the variable tumour growth. This
variation meant mice were enrolled in the study at different times,
with the net consequence that we could not be certain that animals
entered the study at equivalent stages of cancer development.
Using the data matching procedure we only examined CPP scores
during the likely critical study time of the 10 days before
euthanasia. Although this method of processing the data was not
ideal, it does not detract from our main conclusion that the
increased preference for morphine in cancer mice relative to
controls indicated the emergence of pain.
Another study objective was to investigate the need for
refinements if there was evidence of pain following tumour
implantation. To this end we tested if a pre-procedural dose of
meloxicam (5 mg/kg) was an appropriate method of controlling
post-surgical in the Hargreaves study. Mice seem to require
relatively high doses of NSAIDs [26,59] compared to the
recommended rates for pain prevention in rats [23]. This was
therefore a comparatively low pre-procedural dose, and was based
on investigators’ concerns over possible later impacts on tumour
development. Although a relatively common reason for excluding
analgesics from cancer studies [60] there was no such effect here.
In agreement with behavioural and other physiological evidence
[23,26] 5 mg/kg meloxicam also did not prevent post-surgical
hyperalgesia, so switching to an alternative (e.g. buprenorphine)
could be a refinement option, and is one that has already been
shown to be less likely to interact with cancer study results [33]
than other NSAIDs or opioids.
The effects of morphine were also assessed on euthanasia days
when tumours were at an advanced stage. This delayed euthanasia
by 75 minutes, but was justifiable since any positive effects could
establish if the conditioning dose of morphine was analgesic. If so,
this would provide further evidence of pain and establish if this was
a refinement option in studies with a strong case for prolonging
data collection. Although tumour-bearing mice travelled less and
groomed more before morphine, our ability to detect any positive
effects was confounded by several non-specific effects of drug
treatment. Despite the pre-treatment differences, morphine
increased the distance travelled and the frequency of bouts of
inactivity and rearing in all mice including the controls (Figure 9).
Such non-specific effects of opioids on behaviour are well
documented [1,61–64], and we continue to find these can subvert
attempts to confirm beneficial effects in studies of post-operative
pain in rats in mice [31,65,66]. However, morphine had little
influence on grooming in normal mice, and there were indications
of post-treatment reductions in grooming in the cancer groups
(Figure 9c). Grooming behaviour has previously been concluded
to be important for assessing effects due to abdominal surgery or
other manipulation likely to induce acute visceral discomfort
[30,31,56,67], cancer [68], arthritis [69] and also shows pattern
alterations during stress [70]. Perhaps consistent with stress, the
cancer-bearing mice were less frequently inactive (unable to rest)
prior to morphine (Figure 9d), but again, post-treatment effects
were similar in all mice so no positive outcomes were detectable.
To maximise the welfare of mice used in cancer studies the
refinements resulting from this work would ideally be widely
applicable; such as to soft tissue cancers in general. Present results
support this, at least for bladder cancer, since we implanted cells
via 2 very different approaches (one surgical, one not) yet still
found a commonality in pain symptoms over the final 7–10 study
days. An obvious general recommendation would be to monitor
animals as closely as possible during this time, possibly adding
hyperalgesia and/or behaviour assessments to standard end-point
determinations. We cannot state the extent to which behaviour or
nociceptive changes should necessitate euthanasia, but increased
grooming and the highly significant effects on rearing during
cancer development indicate both could be useful. Although the
effects on rearing could be also have been caused by malaise or
some associated lethargy, they still indicated compromised welfare.
Nociceptive assessments, however, require specialised equipment
(e.g. Hargreaves apparatus) and routine CPP testing would
obviously be implausible. The simplest alternative is to rely on
weight changes, and accordingly, current model-specific guidelines
suggest animals with solid internalised tumours and showing
‘severe’ cachexia (amounting to between 15 to 20% of baseline
body weight) should be euthanased [11]. However, all cancer-
bearing mice presently remained within these limits, with the
greatest weight loss in the behaviour study being in the tumour
group (4.6%). In the CPP study we found the greatest loss was 5 g
in a tumour bearing mouse during the final 10 study days. We
predicted that the repeated morphine treatments might minimise
differences between the tumour and control groups, but seemingly
not. One possible explanation is that although both the control
and tumour groups were palpated daily, those with tumours may
have experienced additional discomfort. We have previously
shown that palpation adversely affects the behaviour of rats with
bladder cancer [71]. Whether this was currently the case is
speculative, but it is nevertheless advisable to be cautious in the
manner and frequency of palpation. Body weight assessments
should also be adjusted for increased mass due to progression of
cancer. Although this was attempted it was found to be difficult, as
in any model where tumours are internalised. In any event there
was no effective relationship between body weight changes, ex-vivo
tumour burden and survival (measured by study days from
detection to euthanasia). Thus, even if palpation was an effective
measure of burden, this would not have been useful in forecasting
the need for euthanasia. A more likely scenario was that pain
severity and survival were more closely governed by the tissues
impacted on during cancer growth rather than burden per se. A
better approach would be to use more sophisticated methods such
as imaging tumours. We plan to use this in future studies to
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investigate relationships between tumour morphology and welfare,
and the general applicability of the CPP and other findings where
tumours grow in tissues where they are differentially likely to cause
pain. As the majority of evidence indicated the mice were painful
despite only moderate weight loss, we suggest protocols relying on
this as a primary welfare indicator might consider a more
conservative end-point; such as any consistent weight loss over a 2
to 3 day period in an otherwise healthy mouse. In studies where
more consistent tumour growth is achieved and study duration can
be estimated more accurately, our results suggest end-points might
be brought forward by at least one week. The precise time is
obviously still difficult to identify, but experienced care staff can be
exceptionally capable in estimating survival.
A fundamental 3Rs principle is to obtain maximum from the
least number of animals, but without compromising scientific
integrity. By applying several different assessment methods we
hoped to detect cancer pain or other negative impacts on welfare
as reliably as possible. Using separate study groups, although a
possible weakness, had the major advantage of minimising the
burden of testing on individual mice. Indeed, the impact of high
intensity testing may be the reason that at least one report has
emerged where a range of different ‘quality of life’ assessments
failed to demonstrate negative consequences in a rat neuropathic
pain model [50]. We believe the present series of experiments
achieved a good level of precision due to the consistency of
findings despite some substantial methodological variations.
Overall, our studies were conducted in a manner that closely
complied with the 3Rs principle of reduction; the majority of data
being collected in mice already undergoing cancer trials. However,
this meant studying the female mice our colleagues routinely use;
due to the greater ease of implanting tumours via the urethra.
Oestrus stage could therefore have impacted on our results
depending on what stage coincided with conditioning, such as by
altering the sensitivity of the mice to morphine. The mice were
singly housed, but not isolated. They were also fully acclimated
and never in contact with male mice, thus over the course of the
study the mice would have undergone several oestrus cycles. It was
not feasible to attempt to determine the impact of this on results
due to the additional sampling that would have been required. We
could have implemented measures to disrupt or halt oestrus,
however, the relatively frequent morphine treatments may have
caused this already. Determining oestrus stage would also have
been very time consuming, and could also have been counterpro-
ductive to results. There is extensive literature on sex and strain
differences in response to pain and to drug treatment [72–76], so
ideally we would repeat the work to establish if the CPP findings
generalise to male mice also. However, this would necessitate
either surgical tumour implantation, or the more invasive
approach of catheterising the urethra of males, both of which
could render results questionable. Overall, we argue that it is
unlikely that only using female mice significantly weakened our
main findings. It could also have been advantageous had we been
able to apply the mouse grimace scale (MGS) as an adjunct to the
various other measurement parameters [59,77,78]. However, the
work was completed prior to its development, and the quality of
video recording in the behaviour study, together with the method
of filming for analysis by HCS meant the data were not suitable for
retrospective analysis using this approach.
Conclusions
The essence of this work was to address a recently highlighted
need for more appropriate (systems-based) methods of analgesic
drug screening, and the development of more relevant transla-
tional pain models. We used a common mouse cancer model and
multiple test methods to simultaneously address a second but no
less important aim. This was to establish if cancer has a negative
impact on the welfare of mice (predictably caused by pain), as this
would demand greater effort in refining present end-point
guidelines. The work constitutes the most comprehensive series
of studies so far undertaken to determine whether bladder cancer
is painful to mice. We showed reduced body condition and weight,
changes in spontaneous behaviour, and the development of
peripheral sensitivity (hyperalgesia) as tumours developed. Added
to this we used the CPP paradigm as a means of offering mice the
opportunity to self-report on any awareness of pain. Those with
cancer spent longer in an environment where they previously
experienced the effects of morphine than mice conditioned to
morphine alone. Another critical finding was that morphine
seeking was closely linked (increased) with tumour burden.
However, the validity of our conclusion that these effects indicated
pain hinges on whether mice sought morphine as a result of its
association with pain relief. It also assumes that the various other
changes provide complementary evidence of this. We argue that
according to the triangulation principle these results collectively
provide convincing evidence of the presence of clinical-type pain
in this mouse cancer model. If not pain, there was at least very
strong evidence of negative impacts on welfare highlighting a need
for a range of possible refinements. Mice in this bladder cancer
model could benefit from removal at least 7, and possibly even 10
days prior to the scheduled end-point. Relying only on weight
changes or other model-specific signs may not be sufficient to
ensure mice do not experience pain before they are euthanased.
Rearing deficits may be a useful early indicator of the onset of
adverse effects. We found no evidence that provision of morphine
was detrimental either to cancer development or to the welfare of
mice. In mice implanted surgically there were also no obvious
effects of a pre-surgery dose of meloxicam either on post-surgery
nociception or tumour development. A more refined surgical
protocol might be one using a more appropriate dose of an
NSAID for pain prevention, but this would require preliminary
work to determine how these or other pharmacological candidates
might impact on result validity. However, depending on the
sensitivity of required outcomes, future studies of this type might
involve buprenorphine; where it has been shown in at least one
cancer study to have negligible or even beneficial effects in terms
of both welfare refinement and result validity [33]. In light of the
numerous other examples where CPP testing has now been
applied to assess centralised pain in models other than cancer, we
also conclude that CPP testing offers a method of increasing the
translational relevance of the results of analgesic screening studies.
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